All In Biotech

Drug Trial Radar · NCT07792408

Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

148

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Mar 11, 2027

Study completion Mar 20, 2027

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.

Conditions

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

  • VX-407Drug

    Tablets for Oral Administration.

  • LNG/EEDrug

    Combination Tablets for Oral Administration.

  • NGM/EEDrug

    Combination Tablets for Oral Administration.

  • NET/EEDrug

    Combination Tablets for Oral Administration.

  • DRSP/EEDrug

    Combination Tablets for Oral Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of LNG/EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
  2. Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31
  3. Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of NET and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23
  4. Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of DRSP and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
  5. Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG/EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
  6. Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31
  7. Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of NET and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23
  8. Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of DRSP and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences - Beaumont Clinic Montreal

    Montreal, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.